Updated 8th September 2007

As of 8th September 2007 until the end of 2008 we will not be able to respond to new customer enquiries. All current customers and projects remain fully supported and all recent orders that have been accepted are being processed normally. Please see the Press Release below for further details. Thank you.

About GeneDetect
Contact page: Contact details
Click here for the Latest News

2006/2007 Product Catalog (1.18Mb .pdf file)
Current price-list

An Overview of in situ hybridization
In Situ hybridization Protocols
For a list of recent publications: Click here
In situ hybridization blog (coming)


Track your package


Press Release 
GeneDetect® announces major alliance with leading European Pharmaceutical and Diagnostics Company to perform contract gene expression and biomarker validation assays. GeneDetect to receive upfront payment and equity investment.
Saturday September 8, 8:00am ET 

Auckland (BUSINESS WIRE) September 8, 2007. GeneDetect (Bradenton, Florida and Auckland, New Zealand), a leading supplier of products and services to academic and government research institutions as well as pharmaceutical and biotechnology companies, announced today that it has entered into a major alliance with a leading European Pharmaceutical and Diagnostic company (THE COMPANY)  to perform gene expression and biomarker validation assays. The contract will last until the end of 2008. GeneDetect will receive an upfront payment and equity investment as part of the alliance.

The popular branded GeneDetect® and GreenStar hyperlabeled gene probe product ranges are used to measure gene expression in tissue samples. 

"The GeneDetect® and GreenStar hyperlabeled gene probe product ranges are used worldwide everyday by researchers in leading research institutes and companies for this purpose and are widely cited in the literature in leading scientific journals" said GeneDetect Chairman and Chief Executive Officer Dr Paul E Hughes. "It is a natural progression then that we begin to work closely with major Pharmaceutical companies on biomarker validation. While we are focused on this major alliance we will ensure all current customers and projects remain fully supported. However since this major alliance will consume most of our production and screening capacity during this time we will be unable to accept new customers and enquiries and we apologize in advance for any inconvenience this may cause". 

About GeneDetect

GeneDetect is a privately owned bioscience company with offices located in North America (Bradenton, Florida) and the Asia-Pacific region (Auckland, New Zealand). 

We develop, manufacture and market more than 4,000 products for the life sciences market. The company is globally focused with customers in over 40 countries and uses cutting edge e-commerce functionality to allow scientists worldwide to order its products online. Real-time pricing in multiple currencies, multi-currency billing, real-time credit card processing and a specialized ability to ship perishable goods to any location on the planet within 96 hours ensures a global customer base. 

Contacts
Web site: http://www.genedetect.com



About "THE COMPANY"

Headquartered in Basel, Switzerland, THE COMPANY is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics and employs roughly 75,000 people in 150 countries. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life.

In 2006, the combined sales of the Pharmaceuticals and Diagnostics Division totaled over 40.0 billion Swiss francs.

© 2000-2007 GeneDetect.com Ltd. 
GeneDetect® GreenStar^TM rAVE^TM, deprAVE^TM, crAVE^TM, GenPep^TM and OptiScript^TM are trademarks of GeneDetect.com Limited.